BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cagno V, Magliocco G, Tapparel C, Daali Y. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol 2021;128:621-4. [PMID: 33232578 DOI: 10.1111/bcpt.13537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Islam MA, Kibria MK, Hossen MB, Reza MS, Tasmia SA, Tuly KF, Mosharof MP, Kabir SR, Kabir MH, Mollah MNH. Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. Sci Rep 2023;13:4685. [PMID: 36949176 DOI: 10.1038/s41598-023-31276-6] [Reference Citation Analysis]
2 Piplani S, Singh P, Petrovsky N, Winkler DA. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics. Int J Mol Sci 2023;24. [PMID: 36835602 DOI: 10.3390/ijms24044192] [Reference Citation Analysis]
3 Sarker B, Rahaman MM, Islam MA, Alamin MH, Husain MM, Ferdousi F, Ahsan MA, Mollah MNH. Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections. PLoS One 2023;18:e0281981. [PMID: 36913345 DOI: 10.1371/journal.pone.0281981] [Reference Citation Analysis]
4 Yu H, Li L, Huffman A, Beverley J, Hur J, Merrell E, Huang HH, Wang Y, Liu Y, Ong E, Cheng L, Zeng T, Zhang J, Li P, Liu Z, Wang Z, Zhang X, Ye X, Handelman SK, Sexton J, Eaton K, Higgins G, Omenn GS, Athey B, Smith B, Chen L, He Y. A new framework for host-pathogen interaction research. Front Immunol 2022;13:1066733. [PMID: 36591248 DOI: 10.3389/fimmu.2022.1066733] [Reference Citation Analysis]
5 Harrach S, Haag J, Steinbüchel M, Schröter R, Neugebauer U, Bertrand J, Ciarimboli G. Interaction of Masitinib with Organic Cation Transporters. Int J Mol Sci 2022;23. [PMID: 36430667 DOI: 10.3390/ijms232214189] [Reference Citation Analysis]
6 Herrera-rodulfo A, Andrade-medina M, Carrillo-tripp M. Repurposing Drugs as Potential Therapeutics for the SARS-Cov-2 Viral Infection: Automatizing a Blind Molecular Docking High-throughput Pipeline. Biomedical Engineering 2022. [DOI: 10.5772/intechopen.105792] [Reference Citation Analysis]
7 Rieder AS, Deniz BF, Netto CA, Wyse ATS. A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease. Neurotox Res 2022. [PMID: 35917086 DOI: 10.1007/s12640-022-00542-2] [Reference Citation Analysis]
8 Puppala RK, Subbaiah N, Maheswaramma KS. Trace level detection and quantification of genotoxic impurities 3‐amino‐4‐methylbenzoate, 3‐amino‐4‐methylbenzoic acid, and 3‐(4‐methyl‐1H‐imidazol‐1‐yl)‐5‐(trifluoromethyl) aniline in Nilotinib dihydrochloride active pharmaceutical ingredient using liquid chromatography‐tandem mass spectrometry. Separation Science Plus 2022;5:349-356. [DOI: 10.1002/sscp.202200047] [Reference Citation Analysis]
9 Pipitò L, Rujan RM, Reynolds CA, Deganutti G. Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. Bioessays 2022;:e2200060. [PMID: 35843871 DOI: 10.1002/bies.202200060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Agrawal P, Sambaturu N, Olgun G, Hannenhalli S. A Path-Based Analysis of Infected Cell Line and COVID-19 Patient Transcriptome Reveals Novel Potential Targets and Drugs Against SARS-CoV-2. Front Immunol 2022;13:918817. [DOI: 10.3389/fimmu.2022.918817] [Reference Citation Analysis]
11 Strobelt R, Adler J, Paran N, Yahalom-Ronen Y, Melamed S, Politi B, Shulman Z, Schmiedel D, Shaul Y. Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Sci Rep 2022;12:5758. [PMID: 35388061 DOI: 10.1038/s41598-022-09664-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kouznetsova VL, Zhang A, Miller MA, Tatineni M, Greenberg JP, Tsigelny IF. Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs. J Explor Res Pharmacol 2022;7:17-29. [DOI: 10.14218/jerp.2021.00050] [Reference Citation Analysis]
13 Dokainish HM, Re S, Mori T, Kobayashi C, Jung J, Sugita Y. The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein. Elife 2022;11:e75720. [PMID: 35323112 DOI: 10.7554/eLife.75720] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
14 Guo Y, Esfahani F, Shao X, Srinivasan V, Thomo A, Xing L, Zhang X. Integrative COVID-19 biological network inference with probabilistic core decomposition. Brief Bioinform 2022;23. [PMID: 34791019 DOI: 10.1093/bib/bbab455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, Waldhoer M, Zimmermann M, Buzón MJ, Genescà M, Selent J. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci 2021;22:13592. [PMID: 34948390 DOI: 10.3390/ijms222413592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Siminea N, Popescu V, Sanchez Martin JA, Florea D, Gavril G, Gheorghe AM, Iţcuş C, Kanhaiya K, Pacioglu O, Popa IL, Trandafir R, Tusa MI, Sidoroff M, Păun M, Czeizler E, Păun A, Petre I. Network analytics for drug repurposing in COVID-19. Brief Bioinform 2021:bbab490. [PMID: 34864885 DOI: 10.1093/bib/bbab490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mathez G, Cagno V. Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing. Antivir Chem Chemother 2021;29:20402066211061063. [PMID: 34806440 DOI: 10.1177/20402066211061063] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W, Surendranathan S, Mahmud F, Whatcott R, Thammathong J, Meibohm B, Miller DD, Jonsson CB, Dubey KD. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study. J Chem Inf Model 2021;61:5469-83. [PMID: 34666487 DOI: 10.1021/acs.jcim.1c00524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Peralta-garcia A, Torrens-fontanals M, Stepniewski TM, Grau-expósito J, Perea D, Ayinampudi V, Waldhoer M, Zimmermann M, Buzón MJ, Genescà M, Selent J. Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells.. [DOI: 10.1101/2021.09.07.459123] [Reference Citation Analysis]
20 Torres C, Garling A, Taouji S, Calmels C, Andreola ML, Métifiot M. Targeting the Integrated Stress Response Kinase GCN2 to Modulate Retroviral Integration. Molecules 2021;26:5423. [PMID: 34500856 DOI: 10.3390/molecules26175423] [Reference Citation Analysis]
21 Gawriljuk VO, Zin PPK, Puhl AC, Zorn KM, Foil DH, Lane TR, Hurst B, Tavella TA, Costa FTM, Lakshmanane P, Bernatchez J, Godoy AS, Oliva G, Siqueira-Neto JL, Madrid PB, Ekins S. Machine Learning Models Identify Inhibitors of SARS-CoV-2. J Chem Inf Model 2021. [PMID: 34387990 DOI: 10.1021/acs.jcim.1c00683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
22 Dokainish HM, Re S, Mori T, Kobayashi C, Jung J, Sugita Y. The Inherent Flexibility of Receptor Binding Domains in SARS-CoV-2 Spike Protein.. [DOI: 10.1101/2021.08.06.455384] [Reference Citation Analysis]
23 Yuce M, Cicek E, Inan T, Dag AB, Kurkcuoglu O, Sungur FA. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins 2021. [PMID: 34169568 DOI: 10.1002/prot.26164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
24 Guo Y, Esfahani F, Shao X, Srinivasan V, Thomo A, Xing L, Zhang X. Integrative COVID-19 Biological Network Inference with Probabilistic Core Decomposition.. [DOI: 10.1101/2021.06.23.449535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Tsegay KB, Adeyemi CM, Gniffke EP, Sather DN, Walker JK, Smith SEP. A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2. Front Pharmacol 2021;12:685308. [PMID: 34194331 DOI: 10.3389/fphar.2021.685308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
26 Ahmad S, Waheed Y, Ismail S, Bhatti S, Abbasi SW, Muhammad K. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme. Molecules 2021;26. [PMID: 33800013 DOI: 10.3390/molecules26051446] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]